Mount Sinai Researchers Identify Subtle Changes that May Occur in Neural Circuits Due to Cocaine Addiction
Research May Offer a Unique Pathway for Targeting New Therapeutics for Addiction Treatment
A research team from the Friedman Brain Institute of the Icahn School of Medicine at Mount Sinai has published evidence that shows that subtle changes of inhibitory signaling in the reward pathway can change how animals respond to drugs such as cocaine. This is the first study to demonstrate the critical links between the levels of the trafficking protein, the potassium channels’ effect on neuronal activity and a mouse’s response to cocaine. Results from the study are published in the peer-reviewed journal Neuron on May 7, 2014.
The authors investigated the role of sorting nexin 27 (SNX27), a PDZ-containing protein known to bind GIRK2c/GIRK3 channels, in regulating GIRK currents in dopamine (DA) neurons on the ventral tegmental area (VTA) in mice.
“Our results identified a pathway for regulating the excitability of the VTA DA neurons, highlighting SNX27 as a promising target for treating addiction,” said Paul A. Slesinger, PhD, Professor, Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai.
“Future research will focus on the role that potassium channels and trafficking proteins have in models of addiction,” said Dr. Slesinger.
Dr. Slesinger was the lead author of the study and joined by Michaelanne B. Munoz from the Graduate Program in Biology, University of California, San Diego and the Peptide Biology Laboratories, The Salk Institute for Biological Studies, La Jolla, California.
The research was supported by grants from the National Institute on Drug Abuse, the Salk Institute Chapman Foundation, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology/Neurosurgery, and Orthopedics in the 2019-2020 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology and Mount Sinai South Nassau is ranked 35th nationally for Urology. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and Mount Sinai South Nassau are ranked regionally.